r-SNM System for Overactive Bladder
Urinary urgency-frequency
ApprovedActive
Key Facts
About Axonics
Axonics, founded in 2012 and headquartered in Irvine, California, established itself as a disruptive force in the sacral neuromodulation (SNM) market with its full-body MRI-compatible, rechargeable implant systems for urinary urgency incontinence and fecal incontinence. Its technology challenged incumbent offerings with a 15+ year battery life and a streamlined implant procedure. Acquired by Boston Scientific in early 2024 for $3.7 billion, Axonics now functions as a key growth asset within Boston Scientific's urology portfolio, leveraging the larger company's global commercial infrastructure to expand access to its advanced neuromodulation therapies.
View full company profile